Erythropoietin-derived peptide activating the innate repair receptor without stimulating RBC production. Studied for neuropathy and metabolic syndrome.
Pre-filled with standard ARA-290 values. Adjust as needed.
Standard: 2–4mg subcutaneously once daily. Clinical trial protocol: 4mg daily for 28 days. No erythropoietic effect — safe in competitive sports.
Blood markers to track
Note: EPO-derived but no RBC stimulation. Phase 2 trials for diabetic neuropathy. No doping concern.
Log CBC (no RBC increase) and HbA1c across draws and let StackAI analyze your response. Free to start.
Track my ARA-290 labs free →